Cargando…

Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study

Neovascular age-related macular degeneration (nAMD) leads to visual impairment if not treated promptly. Intravitreal anti-VEGF drugs have revolutionized nAMD treatment in the past two decades. We evaluated the visual outcomes of anti-VEGF treatment in nAMD. A real-life population-based cohort study....

Descripción completa

Detalles Bibliográficos
Autores principales:	Korva-Gurung, Ida, Kubin, Anna-Maria, Ohtonen, Pasi, Hautala, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384898/ https://www.ncbi.nlm.nih.gov/pubmed/37513839 http://dx.doi.org/10.3390/ph16070927

Ejemplares similares

Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland
por: Korva-Gurung, Ida, et al.
Publicado: (2023)

Visual outcomes of observation, macular laser and anti-VEGF in diabetic macular edema in type 1 diabetes: a real-world study
por: Wirkkala, Joonas, et al.
Publicado: (2022)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration
por: Vottonen, Pasi, et al.
Publicado: (2013)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2017)

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes
por: Horner, Faye, et al.
Publicado: (2021)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands
por: Verbraak, Frank D., et al.
Publicado: (2020)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

Encouraging visual outcomes in children with idiopathic and JIA associated uveitis: a population-based study
por: Siiskonen, Mira, et al.
Publicado: (2023)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration
por: Onwuka, Oluchukwu, et al.
Publicado: (2023)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1
por: Özkaya, Abdullah, et al.
Publicado: (2018)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
por: Corazza, Paolo, et al.
Publicado: (2021)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2016)

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy
por: Prea, Selwyn M., et al.
Publicado: (2015)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration
por: Mantel, Irmela, et al.
Publicado: (2019)

Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy
por: Cao, Xuan, et al.
Publicado: (2022)

Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration
por: Miyata, Manabu, et al.
Publicado: (2021)

Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment
por: Yeter, D.Y., et al.
Publicado: (2021)

OCT-Derived Radiomic Features Predict Anti–VEGF Response and Durability in Neovascular Age-Related Macular Degeneration
por: Kar, Sudeshna Sil, et al.
Publicado: (2022)

Suspension of Anti-VEGF Treatment Does Not Affect Expansion of RPE Atrophy in Neovascular Age-Related Macular Degeneration
por: Chujo, Shinichiro, et al.
Publicado: (2023)

Decrease in Anti-VEGF Injections After Post-injection Endophthalmitis in Patients With Neovascular Age-Related Macular Degeneration
por: Binczyk, Natalia M., et al.
Publicado: (2023)

Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration
por: Siempis, Thomas, et al.
Publicado: (2019)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Leung, Ella H, et al.
Publicado: (2023)

Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry
por: Riemer, Tommes, et al.
Publicado: (2023)

Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration
por: Nassisi, Marco, et al.
Publicado: (2023)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema, Muhammad Raza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q8fgoitg6tqb6sb4sb6b0ftnv7